Advertisement

Thymosin: An Innovative Approach to the Treatment of Chronic Hepatitis B

  • Milton G. Mutchnick
  • Glen D. Cummings
  • Jay H. Hoofnagle
  • David A. Shafritz

Abstract

Chronic hepatitis B virus infection is a common disease afflicting 300 million people worldwide, including approximately one million Americans who are carriers of the hepatitis B surface antigen (HBSAg). Many such carriers have concomitant chronic liver disease and are at risk for developing cirrhosis, liver failure and hepatocellular carcinoma (1, 2). Impaired effectiveness of the host cellular immune mechanisms in clearing hepatitis B virus (HBV) infected hepatocytes has been proposed to explain development of chronic HBV infection (3, 4).

Keywords

Hepatitis Delta Virus Peripheral Blood Mononuclear Thymic Hormone Chronic Woodchuck Hepatitis Virus Woodchuck Hepatitis Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Seeff LB, Koff RS: Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection. Sem Liver Dis 6:11–22, 1986CrossRefGoogle Scholar
  2. 2.
    Hoofnagle JH, Alter HJ. Chronic viral hepatitis. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 97–113, 1984Google Scholar
  3. 3.
    Thomas HC, Lever AML, Scully LJ, Pignatelli M: Approaches to the treatment of hepatitis B virus and Delta-related liver disease. Sem Liver Dis 6:34–41, 1986CrossRefGoogle Scholar
  4. 4.
    Dienstag JL: Immunologic mechanisms in chronic viral hepatitis. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 135–66, 1984Google Scholar
  5. 5.
    Alexander GJM, Williams R: Natural history and therapy of chronic hepatitis B virus infection. Am J Med 85:143–146, 1988PubMedCrossRefGoogle Scholar
  6. 6.
    DiBisceglie AM, Hoofnagle JH: Antiviral therapy of chronic viral hepatitis. Am J Gastro 85:650–654, 1990Google Scholar
  7. 7.
    Lever AML: Treatment of the chronic hepatitis B virus carrier state. J Infect 16:221–229, 1988PubMedCrossRefGoogle Scholar
  8. 8.
    Aach, RD: The treatment of chronic type B viral hepatitis. Ann Int Med 109:89–91, 1988PubMedGoogle Scholar
  9. 9.
    Perrillo RP, Regenstein FG, Peters MG, et al: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. Ann Int Med 109:95–100, 1988PubMedGoogle Scholar
  10. 10.
    Hoofnagle JH, Peters M, Mullen KD, et al: Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318–1325, 1988PubMedGoogle Scholar
  11. 11.
    Perrillo RP, Schiff ER, Davis GL, et al: A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Eng J Med 323:295–301, 1990CrossRefGoogle Scholar
  12. 12.
    Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa (sic) therapy. Arch Intern Med 147:1577–1580, 1987PubMedCrossRefGoogle Scholar
  13. 13.
    Low TLK, Goldstein AL: Thymosins: structure, function and therapeutic applications. Thymus 6:27–42, 1984PubMedGoogle Scholar
  14. 14.
    Goldstein AL, Guha A, Zatz MM, et al: Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA 69:1800–1803, 1972PubMedCrossRefGoogle Scholar
  15. 15.
    Wetzel R, Heyneker HL, Goeddel DV, et al: Production of biologically active Nα-desacetyl thymosin αl in E. coli through expression of a chemically synthesized gene. Biochem 19:6096–6104, 1980CrossRefGoogle Scholar
  16. 16.
    Low TLK, Thurman GB, McAdoo M, et al: I. Isolation, characterization and biological activities of thymosin al and polypeptide α1 from calf thymus. J Biol Chem 254:981–86, 1979PubMedGoogle Scholar
  17. 17.
    Marshall GD, Thurman GB, Rossio JL, Goldstein AL: In vivo generation of suppressor T-cells by thymosin in congenitally athymic nude mice. J Immunol 126:741–44, 1981PubMedGoogle Scholar
  18. 18.
    Mutchnick MG, Prieto JA, Schaffner JA, Weller FE. Thymosin modulation of regulatory T cell function. Clin Immunol Immuno 23:626–33, 1982CrossRefGoogle Scholar
  19. 19.
    Sztein MB, Serrate SA, Goldstein AL: Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 83:6107–6111, 1986PubMedCrossRefGoogle Scholar
  20. 20.
    Serrate SA, Schulof RS, Leondaridis L, et al: Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 139:2338–2343, 1987PubMedGoogle Scholar
  21. 21.
    Favalli C, Jezzi T, Mastino A, et al: Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 20:189–192, 1985PubMedCrossRefGoogle Scholar
  22. 22.
    Baxevanis CN, Reclos GJ, Perez S, et al: Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin enhances while thymosin B4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharm 13:133–141, 1987CrossRefGoogle Scholar
  23. 23.
    Svedersky LP, Hui A, May L, et al: Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by N alpha - desacetylthmosin αl. J Immunol 12:244–247, 1982Google Scholar
  24. 24.
    Sztein MB, Goldstein AL: Thymic hormones-a clinical update. Springer Sem Immunopathol 9:1–18, 1986Google Scholar
  25. 25.
    Mutchnick MG, Missirian A, Johnson AG: Lymphocyte cytotoxicity in human liver disease using rat hepatocyte monolayer cultures. Clin Immunol Immunopathol 16:423–437, 1980PubMedCrossRefGoogle Scholar
  26. 26.
    Mutchnick MG, Schaffner JA, Prieto JA, et al: Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sci 28:328–334, 1983PubMedCrossRefGoogle Scholar
  27. 27.
    Shen S, Josselson J, McRoy C, et al: Effects of thymosin alpha-1 (TA-1) on peripheral T-cell and Heptavax-B vaccination (V) in previously non-responsive hemodialysis (HD) patients (Pts). Hepatology 7:1120, 1987Google Scholar
  28. 28.
    Mutchnick MG, Appelman HD, Chung HT, et al: Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology (in press).Google Scholar
  29. 29.
    Knodell RG, Ishak KG, Black WC, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–35, 1981PubMedCrossRefGoogle Scholar
  30. 30.
    Mutchnick MG, Lee HH, Hollander DI, et al: Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin β4 levels in patients with inflammatory bowel disease. Clin Immunol Immunopathol 47:84–92, 1988PubMedCrossRefGoogle Scholar
  31. 31.
    Shafritz DA, Shouval D, Sherman HI, et al: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 305:1067–1073, 1981PubMedCrossRefGoogle Scholar
  32. 32.
    Zav’yalov VP, Denesyuk AI, Zav’yalova GA: Theoretical analysis of conformation and active sites of interferons. Immunol Lett 22:173–181, 1989PubMedCrossRefGoogle Scholar
  33. 33.
    Korba BE, Tennant BC, Cote PJ, Mutchnick M, Gerin JL: Treatment of chronic woodchuck hepatitis virus infection with thymosin alpha-1. Hepatology 12:880, 1990Google Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Milton G. Mutchnick
    • 1
  • Glen D. Cummings
    • 1
  • Jay H. Hoofnagle
    • 2
  • David A. Shafritz
    • 3
  1. 1.Department of MedicineWayne State University School of MedicineDetroitUSA
  2. 2.Liver Disease Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaUSA
  3. 3.Liver Research CenterAlbert Einstein College of MedicineNew YorkUSA

Personalised recommendations